1. Home
  2. MTR vs NERV Comparison

MTR vs NERV Comparison

Compare MTR & NERV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • MTR
  • NERV
  • Stock Information
  • Founded
  • MTR 1979
  • NERV 2007
  • Country
  • MTR United States
  • NERV United States
  • Employees
  • MTR N/A
  • NERV N/A
  • Industry
  • MTR Oil & Gas Production
  • NERV Biotechnology: Pharmaceutical Preparations
  • Sector
  • MTR Energy
  • NERV Health Care
  • Exchange
  • MTR Nasdaq
  • NERV Nasdaq
  • Market Cap
  • MTR 11.7M
  • NERV 10.7M
  • IPO Year
  • MTR N/A
  • NERV 2014
  • Fundamental
  • Price
  • MTR $6.13
  • NERV $1.61
  • Analyst Decision
  • MTR
  • NERV Hold
  • Analyst Count
  • MTR 0
  • NERV 1
  • Target Price
  • MTR N/A
  • NERV $5.00
  • AVG Volume (30 Days)
  • MTR 3.7K
  • NERV 15.1K
  • Earning Date
  • MTR 01-01-0001
  • NERV 04-30-2025
  • Dividend Yield
  • MTR 3.00%
  • NERV N/A
  • EPS Growth
  • MTR N/A
  • NERV N/A
  • EPS
  • MTR 0.25
  • NERV 0.19
  • Revenue
  • MTR $731,355.00
  • NERV N/A
  • Revenue This Year
  • MTR N/A
  • NERV N/A
  • Revenue Next Year
  • MTR N/A
  • NERV N/A
  • P/E Ratio
  • MTR $25.12
  • NERV $8.95
  • Revenue Growth
  • MTR N/A
  • NERV N/A
  • 52 Week Low
  • MTR $5.60
  • NERV $1.42
  • 52 Week High
  • MTR $11.99
  • NERV $3.69
  • Technical
  • Relative Strength Index (RSI)
  • MTR 42.62
  • NERV 41.00
  • Support Level
  • MTR $6.02
  • NERV $1.54
  • Resistance Level
  • MTR $6.29
  • NERV $1.89
  • Average True Range (ATR)
  • MTR 0.15
  • NERV 0.11
  • MACD
  • MTR -0.01
  • NERV 0.00
  • Stochastic Oscillator
  • MTR 25.09
  • NERV 22.68

About MTR Mesa Royalty Trust

Mesa Royalty Trust holds net overriding royalty interests in various oil and gas properties located in the: Hugoton field of Kansas, San Juan Basin field of New Mexico, and San Juan Basin Field of Colorado.

About NERV Minerva Neurosciences Inc

Minerva Neurosciences Inc is a clinical-stage biopharmaceutical company. It focuses on the development and commercialization of a portfolio of product candidates to treat patients suffering from central nervous system diseases. The company's pipeline products include MIN-101, MIN-202, and MIN-301. Targeted disorders include schizophrenia, insomnia, depressive disorder, and Parkinson's disease. Its product portfolio and potential indications include Roluperidone for the treatment of negative symptoms in patients with schizophrenia; Seltorexant, for the treatment of insomnia disorder and depressive disorder; MIN-117 for the treatment of MDD; and MIN-301 for the treatment of Parkinson's disease.

Share on Social Networks: